EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische Studie

Discrepancy between one-stage clotting and chromogenic factor VIII activity in women with hemophilia A and hemophilia A carriers: a retrospective clinical study

Stephanie Desage, Anne Lienhart, Maissaa Janbain, Hamdi Rezigue, Alexandre Leuci, Yesim Dargaud

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2025.02.031 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Stephanie Desage und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unite d'Hemostase Clinique, Centre de Reference de l'Hemophilie, Hopital Louis Pradel, Lyon, France. Hauptthemen laut MEDLINE: Blood Coagulation, Chromogenic Compounds, Factor VIII, Hemophilia A. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: For every man diagnosed with hemophilia, approximately 1.6 women are expected to be carriers. Carriers are classified based on their factor (F) VIII levels and symptoms, ranging from asymptomatic to mild, either moderate or severe symptoms. Close monitoring is critical for carriers with low FVIII levels or bleeding symptoms, as the bleeding risk is difficult to assess due to inconsistent correlations with routine one-step assay (OSA) measurements. OBJECTIVES: This study hypothesized that the chromogenic FVIII assay (CSA) may provide valuable information for estimating the bleeding risk in some hemophilia carriers. METHODS: This retrospective study included 109 hemophilia A carriers from 2 centers. RESULTS: Among them, 23% had FVIII levels

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood CoagulationChromogenic CompoundsFactor VIIIHemophilia AHeterozygoteAdultFemaleHumansMiddle AgedPregnancyYoung AdultBlood Coagulation TestsHemorrhagePredictive Value of TestsReproducibility of ResultsRetrospective StudiesRisk Factorsvon Willebrand Factor

Stichwörter der Autor:innen

carrierschromogenichemophilia Aone stagewomen

Substanzen

Chromogenic CompoundsF8 protein, humanFactor VIIIvon Willebrand Factor

Autor:innen und Institutionen

  • Unite d'Hemostase Clinique, Centre de Reference de l'Hemophilie, Hopital Louis Pradel, Lyon, France.
  • Deming Department of Internal Medicine, Section of Hematology and Medical Oncology, Tulane School of Medicine, New Orleans, Louisiana, USA.
  • Université Claude Bernard Lyon 1, UR4609 Hemostase & Thrombose, Lyon, France.
  • Unite d'Hemostase Clinique, Centre de Reference de l'Hemophilie, Hopital Louis Pradel, Lyon, France; Université Claude Bernard Lyon 1, UR4609 Hemostase & Thrombose, Lyon, France. Electronic address: gamze.dargaud@chu-ly…

Zitieren

APA

Desage, S., Lienhart, A., Janbain, M., Rezigue, H., Leuci, A., & Dargaud, Y. (2025). Discrepancy between one-stage clotting and chromogenic factor VIII activity in women with hemophilia A and hemophilia A carriers: a retrospective clinical study. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.02.031

Vancouver

Desage S, Lienhart A, Janbain M, Rezigue H, Leuci A, Dargaud Y. Discrepancy between one-stage clotting and chromogenic factor VIII activity in women with hemophilia A and hemophilia A carriers: a retrospective clinical study. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.02.031

BibTeX
@article{Desage2025,
  author = {Desage, Stephanie and Lienhart, Anne and Janbain, Maissaa and Rezigue, Hamdi and Leuci, Alexandre and Dargaud, Yesim},
  title = {Discrepancy between one-stage clotting and chromogenic factor VIII activity in women with hemophilia A and hemophilia A carriers: a retrospective clinical study},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2025.02.031}
}
Kostenlos starten →